Why the study?
The authors sought to investigate DAPT duration and determine factors associated with early DAPT discontinuation and event rates in patients who discontinued DAPT after PCI.
Does DAPT continuation (≥ 3 months) improve composite efficacy outcomes compared to early discontinuation (< 3 months) in patients post-PCI?
Does DAPT continuation (≥ 3 months) improve composite efficacy outcomes compared to early discontinuation (< 3 months) in patients post-PCI?
Early discontinuation of DAPT (<3 months) post-PCI is associated with an increased risk of ischemic events without a significant reduction in major bleeding.
Answers are grounded in this paper and cite their sources.
Early DAPT discontinuation post-PCI warrants caution for ischemic risk; leaves open optimal duration in randomized trials.
In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012-March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3 months post-PCI. Patients without major efficacy or safety events within 3 months after index PCI were included in a landmark analysis set (LAS; n = 7056), and categorized as DAPT ≥ 3 months (continuation) versus < 3 months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P = 0.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P < 0.001). In multivariate regression analysis, age ≥ 75 years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Yokoi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: